Collegium Pharmaceutical Reports Q3 2026 Results with ADHD Portfolio Growth Offsetting Pain Segment Declines
Collegium Pharmaceutical (COLL) reported third-quarter 2026 net product revenue of $216.3 million, a 3% year-over-year increase. The growth was primarily driven by the company's expanding ADHD portfolio, specifically Jornay PM, which saw net revenue rise 24% to $51.9 million due to record prescription volumes and increased prescriber adoption. However, these gains were partially offset by significant headwinds in the pain management segment. The Nucynta franchise experienced a 44% decline in revenue due to intense generic competition, while Xtampza ER revenue fell 9% amid ongoing payer pressure. Despite these challenges, the company reaffirmed its full-year 2026 total revenue guidance of $825 million to $855 million, signaling confidence in its transition toward ADHD as a primary growth driver.
Tickers: $COLL
Topics: Acquisition Integration ADHD Portfolio EBITDA Prescription Data Revenue Growth
Read the full article at Motley Fool
Part of the story Akebia Therapeutics Reports Q3 2026 Financial Results Amid Vafseo Growth and Auryxia Decline (6 articles)